ZYPREXA VELOTAB 5mg Tablets/Orodispersible drug uses, side effects , price in UAE 2023


ZYPREXA VELOTAB 5mg Tablets/Orodispersible Price, Uses, Alternatives, Dose, and more in UAE 2023


ZYPREXA VELOTAB 5mg Tablets/Orodispersible


ZYPREXA VELOTAB 5mg Tablets/Orodispersible Price

ZYPREXA VELOTAB 5mg Tablets/Orodispersible

Company
ELI LILLY & CO LTD.
Form
Tablets/Orodispersible
Last update
2/4/2023, 9:05:09 PM
Visits
462


Price, active substance, and uses of ZYPREXA VELOTAB 5mg Tablets/Orodispersible


462

AED 424


Drug name ZYPREXA VELOTAB 5mg

Active substance Olanzapine

Size : 28 s (7 s Blister x 4)

Concentration: 5mg/Tablet

Type: Tablets/Orodispersible

Company : ELI LILLY & CO LTD.

Import: UK

Uploaded By : Admin

ٍ Visits : 462 visit




 What is Zyprexa Velotab?

Olanzapine is an antipsychotic medicine that affects chemicals in the brain.

The principle of action of olanzapine is that it binds to dopamine and serotonin receptors and influences their action.


Uses of Zyprexa Velotab

Olanzapine is used in the treatment of the following diseases and psychological problems:

Schizophrenia.

Bipolar disorder.

Treatment of mixed mania or severe mania associated with bipolar disorder or schizophrenia.

Treating severe depression.

Treatment of depression associated with bipolar disorder.

What are the contraindications of Zyprexa Velotab?

It is contraindicated in patients who have shown hypersensitivity to the drug or to any of its components.


What are the drug interactions of Zyprexa Velotab?

If you are taking any of the following medicines, tell your doctor or pharmacist, as you may need a dose adjustment or certain tests:

antihistamines

Medicines used in disorders and mental disorders.

barbiturates.

sleeping pills

Alcohol.

High blood pressure treatments.

Heart disease treatments.

carbamazepine;

fluoxetine;

flavoxamine.

omeprazole.

rifampin;

Parkinson s treatments.


How to use Zyprexa Velotab

Take with food if stomach upset.

You should drink plenty of fluids, except for caffeine.

You must follow the diet prescribed by your doctor.

Avoid stopping the medication suddenly without contacting your doctor

If symptoms do not improve within two to three weeks, you should contact your doctor.

The treatment may cause a significant increase in weight, so it is advised to monitor the patient s weight and waist circumference.


What are the forms of Zyprexa Velutab?

5 mg tablets


What are the storage conditions for Zyprexa Velotab?

Store the treatment at room temperature 15-25°C, away from moisture, heat, and light.





All you need to know about ZYPREXA VELOTAB 5mg Tablets/Orodispersible

Welcome to Dwaey, specifically on ZYPREXA VELOTAB 5mg Tablets/Orodispersible page.
This medicine contains an important and useful components, as it consists of Olanzapine.
ZYPREXA VELOTAB 5mg is available in the market in concentration 5mg/Tablet and in the form of Tablets/Orodispersible.
ELI LILLY & CO LTD. is the producer of ZYPREXA VELOTAB 5mg and it is imported from UK.
The most popular alternatives of ZYPREXA VELOTAB 5mg are listed downward .

ZYPREXA VELOTAB 5mg Tablets/Orodispersible Alternatives


Frequently Asked Questions

ZYPREXA VELOTAB 5mg Tablets/Orodispersible for what ?

ZYPREXA VELOTAB 5mg Tablets/Orodispersible uses:

Lets know how to use ZYPREXA VELOTAB 5mg Tablets/Orodispersible

ZYPREXA VELOTAB 5mg Tablets/Orodispersible used for:

  • Schizophrenia
  • Bipolar disorder
  • Agitation
  • Mania

ZYPREXA VELOTAB 5mg Tablets/Orodispersible side effects

  • >10% Orthostatic hypotension (>20%)
  • Weight gain
  • dose dependent (5-40%)
  • Hypertriglyceridemia (<39%)
  • Hypercholesterolemia (<39%)
  • Somnolence
  • dose dependent (6-39%)
  • Extrapyramidal symptoms (EPS)
  • dose dependent (15-32%)
  • Xerostomia (9-22%)
  • Weakness (2-20%)
  • Dizziness (4-18%)
  • Accidental injury (12%)
  • Insomnia (12%)
  • Elevated alanine aminotransferase (ALT) level (5-12%)
  • Constipation (9-11%)
  • Dyspepsia (7-11%)
  • Hyperprolactinemia (30%)
  • Hyperglycemia (12.8%) 1-10% Hypotension (2%)
  • Postural hypotension (1%)
  • Tremor (1%)
  • Asthenia (2%)
  • Akathisia reactions (2%)
  • Parkinsonism reactions (4%) <1% Syncope
  • Sudden cardiac death
  • Hyperglycemia
  • Diabetic coma with ketoacidosis
  • Diabetic ketoacidosis
  • Acute hemorrhagic pancreatitis
  • Venous thromboembolism
  • Immune hypersensitivity reaction
  • Cerebrovascular disease
  • Seizure
  • status epilepticus
  • Suicidal intent
  • Pulmonary embolism
  • Death
  • Neuroleptic malignant syndrome (NMS)
  • Tardive dyskinesia Potentially Fatal: Exacerbation of preexisting diabetes sometimes leading to ketoacidosis. Neuroleptic malignant syndrome.

ZYPREXA VELOTAB 5mg Tablets/Orodispersible contraindications

Angle-closure glaucoma; lactation. IM: History of CVS disease, heart surgery.

ZYPREXA VELOTAB 5mg Tablets/Orodispersible Precaution

Patient w/ cerebrovascular disease or conditions predisposing to hypotension, benign prostatic hyperplasia, paralytic ileus, DM, Parkinson's disease, history of blood dyscrasias, bone marrow depression, hypereosinophilic disorders, myeloproliferative disease, history of seizures or conditions that lower the seizure threshold. IM: Acute MI, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery. Elderly w/ dementia-related psychosis. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and dizziness, if affected, avoid driving and operating machinery. Avoid cigarette smoking. Monitoring Parameters Monitor BP, pulse and resp rate for at least 4 hr after IM inj. Clinical monitoring for hyperglycaemia, plasma lipids and wt. Lactation: Drug enters breast milk; not recommended

ZYPREXA VELOTAB 5mg Tablets/Orodispersible Mode Of action

Olanzapine is an atypical antipsychotic with affinity for serotonin 5-HT2A/2C, dopamine, muscarinic M1-M5, histamine H1 and adrenergic ?1 receptors.

ZYPREXA VELOTAB 5mg Tablets/Orodispersible Interaction

Olanzapine may antagonise the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucuronyl transferase enzymes e.g. omeprazole and rifampicin, may increase olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit olanzapine elimination. Carbamazepine may increase the clearance of olanzapine. Concomitant admin of activated charcoal reduced the oral bioavailability of olanzapine by 50-60%. Caution should be taken when olanzapine is administered with centrally acting drugs and alcohol.